Relapsed/Refractory Epstein Barr Virus infection associated disorders - Pipeline Insight, 2024

This “Relapsed/Refractory Epstein Barr Virus infection associated disorders - Pipeline Insight, 2024,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Relapsed/Refractory Epstein Barr Virus infection associated disorders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Relapsed/Refractory Epstein Barr Virus infection associated disorders Understanding

Relapsed/Refractory Epstein Barr Virus infection associated disorders: Overview

Epstein Barr Virus (EBV) is an extremely successful human herpes virus, which infects essentially all human beings at some time during their life span. EBV infection and the associated immune response results in production of antibodies (seroconversion), which occurs mainly during the first years of life, but may also happen during adolescence or later in life. Infection of adolescents can result in infectious mononucleosis, an acute serious condition characterized by massive lymphocytosis. Transmission of EBV mainly occurs through saliva but can rarely be spread through semen or blood, e.g. through organ transplantations and blood transfusions. EBV transmission through oral secretions results in infection of epithelial cells of the oropharynx. From the epithelial cells EBV can infect B cells, which are the major reservoir for the virus, but other cell types may also become infected. As a result, EBV can shuttle between different cell types, mainly B cells and epithelial cells. Moreover, since the virus can switch between a latent and a lytic life cycle, EBV has the ability to cause chronic relapsing/reactivating infections. Chronic or recurrent EBV infection of epithelial cells has been linked to systemic lupus erythematosus and Sjögren’s syndrome, whereas chronic/recurrent infection of B cells has been associated with rheumatoid arthritis, multiple sclerosis and other diseases. Accordingly, since EBV can shuttle between epithelial cells and B cells, the systemic autoimmune diseases often occur as overlapping syndromes with symptoms and characteristic autoantibodies (e.g. antinuclear antibodies and rheumatoid factors) reflecting epithelial and/or B cell infection.

Relapsed/Refractory Epstein Barr Virus infection associated disorders - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Relapsed/Refractory Epstein Barr Virus infection associated disorders pipeline landscape is provided which includes the disease overview and Relapsed/Refractory Epstein Barr Virus infection associated disorders treatment guidelines. The assessment part of the report embraces, in depth Relapsed/Refractory Epstein Barr Virus infection associated disorders commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Relapsed/Refractory Epstein Barr Virus infection associated disorders collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Relapsed/Refractory Epstein Barr Virus infection associated disorders.
• In the coming years, the Relapsed/Refractory Epstein Barr Virus infection associated disorders market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Relapsed/Refractory Epstein Barr Virus infection associated disorders R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Relapsed/Refractory Epstein Barr Virus infection associated disorders treatment market. Several potential therapies for Relapsed/Refractory Epstein Barr Virus infection associated disorders are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Relapsed/Refractory Epstein Barr Virus infection associated disorders market size in the coming years.
• This in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Relapsed/Refractory Epstein Barr Virus infection associated disorders) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Relapsed/Refractory Epstein Barr Virus infection associated disorders Emerging Drugs Chapters

This segment of the Relapsed/Refractory Epstein Barr Virus infection associated disorders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Relapsed/Refractory Epstein Barr Virus infection associated disorders Emerging Drugs

Nana-val (nanatinostat + valganciclovir): Viracta TherapeuticsThe use of nanatinostat in combination with valganciclovir is a novel therapeutic approach to target EBV+ malignancies, using a low-dose of Viracta’s oral proprietary epigenetic drug, nanatinostat, to target the EBV genome and induce the expression of certain viral kinase genes. These viral genes then activate the antiviral prodrug, valganciclovir, which is converted to ganciclovir in the gut, and disrupts the DNA replication cycle. This disruption then leads to chain termination and killing of the tumor cells by inducing apoptosis.

Relapsed/Refractory Epstein Barr Virus infection associated disorders: Therapeutic Assessment

This segment of the report provides insights about the different Relapsed/Refractory Epstein Barr Virus infection associated disorders drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Relapsed/Refractory Epstein Barr Virus infection associated disorders

There are approx. 3+ key companies which are developing the therapies for Relapsed/Refractory Epstein Barr Virus infection associated disorders. The companies which have their Relapsed/Refractory Epstein Barr Virus infection associated disorders drug candidates in the most advanced stage, i.e. phase II include, Viracta Therapeutics.

Phases

This report covers around 3+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Relapsed/Refractory Epstein Barr Virus infection associated disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Relapsed/Refractory Epstein Barr Virus infection associated disorders: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Relapsed/Refractory Epstein Barr Virus infection associated disorders therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Relapsed/Refractory Epstein Barr Virus infection associated disorders drugs.

Relapsed/Refractory Epstein Barr Virus infection associated disorders Report Insights

• Relapsed/Refractory Epstein Barr Virus infection associated disorders Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Relapsed/Refractory Epstein Barr Virus infection associated disorders Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Relapsed/Refractory Epstein Barr Virus infection associated disorders drugs?
• How many Relapsed/Refractory Epstein Barr Virus infection associated disorders drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Relapsed/Refractory Epstein Barr Virus infection associated disorders?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Relapsed/Refractory Epstein Barr Virus infection associated disorders therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Relapsed/Refractory Epstein Barr Virus infection associated disorders and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Viracta Therapeutics
• Tessa Therapeutics
• Eutilex
• Atara Biotherapeutics

Key Products

• Nana-val (nanatinostat + valganciclovir)
• CD30.CAR-EBVST cells
• EBViNT Cell
• Tab-cel